82,572 Shares in Pfizer Inc. (PFE) Purchased by Cozad Asset Management Inc.

Cozad Asset Management Inc. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 82,572 shares of the biopharmaceutical company’s stock, valued at approximately $2,996,000. Pfizer comprises 0.9% of Cozad Asset Management Inc.’s holdings, making the stock its 27th largest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Fort L.P. purchased a new position in shares of Pfizer in the 2nd quarter valued at about $121,000. W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in shares of Pfizer in the 1st quarter valued at about $132,000. Braun Bostich & Associates Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at about $139,000. Clearwater Capital Advisors LLC purchased a new position in shares of Pfizer in the 1st quarter valued at about $156,000. Finally, Goodwin Daniel L purchased a new position in shares of Pfizer in the 2nd quarter valued at about $171,000. Institutional investors and hedge funds own 68.64% of the company’s stock.

Several equities research analysts have commented on PFE shares. Cantor Fitzgerald set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Monday, August 27th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $42.00 price objective on shares of Pfizer in a research note on Thursday, August 23rd. Deutsche Bank set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 21st. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Finally, Credit Suisse Group set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 28th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $43.27.

In related news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction dated Monday, October 15th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Shares of Pfizer stock opened at $46.23 on Monday. The company has a market cap of $275.20 billion, a PE ratio of 17.45, a P/E/G ratio of 2.30 and a beta of 0.88. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $46.26. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 EPS. As a group, analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 2.94%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.

TRADEMARK VIOLATION WARNING: “82,572 Shares in Pfizer Inc. (PFE) Purchased by Cozad Asset Management Inc.” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/12/03/82572-shares-in-pfizer-inc-pfe-purchased-by-cozad-asset-management-inc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Technical Analysis of Stocks and What It Means

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply